Scleroderma is a chronic and progressive illness affecting multiple organs resulting in disability and death. Remarkably, there are no approved therapies to control scleroderma, and many patients have poor outcomes. The proposal seeks to identify novel synthetic oleananes that can prevent and reverse the scarring process in the skin and lung. It is anticipated that successful accomplishment of the goal of this proposal will lead to the validation of novel agents that in the near future could advance to clinical trials for the treatment of patients with scleroderma and other fibrotic diseases.
|Effective start/end date||9/1/14 → 7/31/17|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (5R03AR065800-03)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.